Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana.
Journal article
Authors / Editors
Research Areas
No matching items found.
Publication Details
Author list: Zash R, Rough K, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, Petlo C, Lockman S, Makhema J, Shapiro RL
Publisher: Oxford University Press (OUP): Policy B - Oxford Open Option C
Publication year: 2018
Journal: Journal of the Pediatric Infectious Diseases Society (2048-7193)
Journal acronym: J Pediatric Infect Dis Soc
Volume number: 7
Issue number: 3
Start page: e148
End page: e151
ISSN: 2048-7193
eISSN: 2048-7207
Languages: English-Great Britain (EN-GB)
Abstract
Among human immunodeficiency virus-positive women in Botswana on the recommended first-line antiretroviral therapy regimen, tenofovir-emtricitabine-efavirenz, initiated within the first or early second trimester, we found no increased risk of stillbirth, neonatal death, preterm/very preterm delivery, or the infant being born small or very small for gestational age. Treatment with tenofovir-emtricitabine-efavirenz <1 year before conception increased the risk of preterm delivery slightly over late-second-trimester treatment initiation (adjusted risk ratio, 1.33 [95% confidence interval, 1.04-1.70]).
Keywords
No matching items found.
Documents
No matching items found.
